Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.
Two steps forward, one step back: an opinionated take on NEJM highlights for January 2018
By
Marc Herant
NEJM
Playing chess against cancer
Tumors are not intelligent, but, because …
Read more
A golden age for gene therapy: an opinionated take on NEJM highlights for December 2017
By
Marc Herant
Biopharma
,
NEJM
Successes in gene therapy for hemophilia B and A
Hemophilia A and B ar…
Read more
Between the very common and the very rare – An opinionated take on NEJM highlights for October 2017
By
Marc Herant
NEJM
Between the very common and the very rare – An opinionated take on NEJ…
Read more
A strong close to a banner year for progress against cancer: an opinionated take on NEJM highlights for December 2016
By
Marc Herant
NEJM
Successful use of CAR-T therapy in a solid tumor
Chimeric Antigen Rece…
Read more
We may figure out cancer before we figure out the healthcare system: an opinionated take on NEJM highlights for November 2016
By
Marc Herant
NEJM
“My name is T-Cell…, James T-Cell”
Immune T-cells are licensed to kill…
Read more
An ad page in the NEJM and the future of cancer care
By
Marc Herant
Providers
,
NEJM
I am not sure how many docs continue to do this, but I still read the …
Read more
An opinionated take on NEJM highlights for October 2016
By
Marc Herant
NEJM
Continued progress in multiple myeloma
About 25,000 patients are diagn…
Read more
An opinionated take on NEJM highlights for August 2016: cleanliness is not next to healthiness, testing before thinking, a long slog for precision medicine
By
Marc Herant
NEJM
There is such a thing as too much hygiene
The prevalence of asthma in …
Read more
NEJM Highlights for July 2016: Bayesians vs. frequentists, PCPs vs. specialists, SGLT-2 vs. GFR
By
Marc Herant
NEJM
Adaptive clinical trials slowly coming of age
In an adaptive clinical …
Read more
NEJM Highlights March 2016: Getting value for money in healthcare, Zika bad news, linking the microbiome to the metabolic syndrome
By
Marc Herant
NEJM
Could Uber happen to healthcare?
A Perspective article that points ou…
Read more
NEJM Highlights Feb 2016: metrics for all, ROI perversion, less memory loss, the value of a kinder gentler residency
By
Marc Herant
NEJM
Defining success in health care
A perspective advertising yeoman’s wor…
Read more
NEJM Highlights December 2015: providing effective healthcare is hard and expensive – but ineffective care can be even more expensive – and defining what expensive means in healthcare is hard
By
Marc Herant
NEJM
A new focus on the diagnostic reliability of clinicians
Two perspectiv…
Read more
NEJM Highlights October 2015: what to do, how to do it, and to whom
By
Marc Herant
NEJM
What are annual physicals for?
Annual physicals are costly (~$10 billi…
Read more
NEJM Highlights September 2015: cells, cells, cells
By
Marc Herant
NEJM
Promise for systemic amyloidosis (and beyond?)
Systemic amyloidosis is…
Read more
NEJM Highlights August 2015: cancer and joints
By
Marc Herant
NEJM
The emergence of a new approach to drug development in cancer
Cancers…
Read more
NEJM Highlights May 2015: a read on ACO performance, progress in cystic fibrosis treatment, yes developing new drugs is expensive, rethinking industry-medicine relationships, CVS Caremark and smoking cessation
By
Marc Herant
NEJM
Early results of the ACO experiment: directionally right, but impact i…
Read more
NEJM Highlights April 2015
By
Marc Herant
NEJM
The rise, fall, and rebirth of the Chinese healthcare system
A fascina…
Read more
NEJM Highlights March 2015: Progress against Crohn’s, PCSK9 inhibitors coming through, comparative effectiveness for diabetic macular edema, Eric Lander encourages the FDA on genomic testing regulation
By
Marc Herant
NEJM
A promising agent for Crohn’s Disease, a miserable illness
Crohn’s is …
Read more
NEJM Highlights February 2015: the most boring month in my NEJM reading memory
By
Marc Herant
NEJM
Our selection from a month with relatively few exciting articles - per…
Read more
NEJM Highlights January 2015: Dengue vaccine, Informed consent, Cancer drugs and Tiering for selection
By
Marc Herant
NEJM
A vaccine for dengue finally nears the market
Dengue is a mosquito tra…
